CO7020863A2 - Profármaco de adrenomedulina basado en polietilenglicol y su uso - Google Patents

Profármaco de adrenomedulina basado en polietilenglicol y su uso

Info

Publication number
CO7020863A2
CO7020863A2 CO14078051A CO14078051A CO7020863A2 CO 7020863 A2 CO7020863 A2 CO 7020863A2 CO 14078051 A CO14078051 A CO 14078051A CO 14078051 A CO14078051 A CO 14078051A CO 7020863 A2 CO7020863 A2 CO 7020863A2
Authority
CO
Colombia
Prior art keywords
adrenomedulin
polyethylene glycol
prodrug based
prodrug
glycol
Prior art date
Application number
CO14078051A
Other languages
English (en)
Spanish (es)
Inventor
Ingo Flamme
Johannes Kobberling
Hans-Georg Lerchen
Nils Griebenow
Rudolf Schohe-Loop
Sven Wittrock
Maria Kollnberger
Frank Wunder
Gorden Redlich
Andreas Knorr
July Marley
Lain Pritchard
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of CO7020863A2 publication Critical patent/CO7020863A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
CO14078051A 2011-11-03 2014-04-10 Profármaco de adrenomedulina basado en polietilenglicol y su uso CO7020863A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11187735 2011-11-03

Publications (1)

Publication Number Publication Date
CO7020863A2 true CO7020863A2 (es) 2014-08-11

Family

ID=47146369

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14078051A CO7020863A2 (es) 2011-11-03 2014-04-10 Profármaco de adrenomedulina basado en polietilenglicol y su uso

Country Status (45)

Country Link
US (3) US9603936B2 (enExample)
EP (2) EP2773376B1 (enExample)
JP (2) JP5995984B2 (enExample)
KR (2) KR101965467B1 (enExample)
CN (2) CN103998063B (enExample)
AR (2) AR088582A1 (enExample)
AU (2) AU2012331244B2 (enExample)
BR (1) BR112014010708B1 (enExample)
CA (1) CA2854134C (enExample)
CL (1) CL2014000948A1 (enExample)
CO (1) CO7020863A2 (enExample)
CR (1) CR20140184A (enExample)
CU (1) CU24184B1 (enExample)
CY (2) CY1117354T1 (enExample)
DK (2) DK2773376T3 (enExample)
DO (2) DOP2014000078A (enExample)
EA (2) EA025631B1 (enExample)
EC (2) ECSP14013326A (enExample)
ES (2) ES2568063T3 (enExample)
GT (1) GT201400085A (enExample)
HR (2) HRP20160285T1 (enExample)
HU (2) HUE036535T2 (enExample)
IL (3) IL232037B (enExample)
IN (1) IN2014CN03290A (enExample)
JO (2) JOP20190001B1 (enExample)
LT (1) LT3075395T (enExample)
MA (1) MA35618B1 (enExample)
ME (1) ME02379B (enExample)
MX (2) MX361287B (enExample)
MY (2) MY173372A (enExample)
NO (1) NO3075395T3 (enExample)
PE (2) PE20141219A1 (enExample)
PH (1) PH12014500998A1 (enExample)
PL (2) PL3075395T3 (enExample)
PT (1) PT3075395T (enExample)
RS (2) RS54623B1 (enExample)
SG (2) SG11201400924TA (enExample)
SI (2) SI2773376T1 (enExample)
TN (1) TN2014000185A1 (enExample)
TR (1) TR201802124T4 (enExample)
TW (2) TWI653051B (enExample)
UA (1) UA111098C2 (enExample)
UY (2) UY34419A (enExample)
WO (1) WO2013064508A1 (enExample)
ZA (1) ZA201600434B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010806A2 (pt) * 2011-11-03 2017-05-02 Bayer Ip Gmbh ligadores à base de tirosina para a ligação reversível de peptídeos
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
JP6685046B2 (ja) * 2014-03-20 2020-04-22 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
CN107001440A (zh) 2014-09-26 2017-08-01 拜耳制药股份公司 稳定化的肾上腺髓质素衍生物及其用途
KR102152437B1 (ko) * 2015-09-18 2020-09-07 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 장시간 작용형 아드레노메둘린 유도체
JP7001285B2 (ja) 2017-03-29 2022-01-19 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
GB201707938D0 (en) * 2017-05-17 2017-06-28 Univ Sheffield Compounds
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
CA3151983A1 (en) * 2019-09-21 2021-03-25 Ozgul TEZGEL Dmso-free synthesis of oligopeptide-modified poly(beta-amino ester)s and their use in nanoparticle delivery systems
JP7498882B2 (ja) * 2019-12-05 2024-06-13 国立大学法人 宮崎大学 異常タンパク質蓄積性神経変性疾患の治療剤
EP4126062A1 (en) * 2020-04-03 2023-02-08 Bayer Aktiengesellschaft Liquid pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
IL297014A (en) * 2020-04-03 2022-12-01 Bayer Ag Pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CN112457218B (zh) * 2020-11-05 2022-08-09 宁夏医科大学 2,4-二氨基丁酸衍生物的合成方法
IL310248A (en) 2021-08-20 2024-03-01 Bayer Ag Process for the preparation of pegylated adrenomedullin, its intermediates and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2025133215A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Use of inactive adrenomedullin precursor for therapeutic purposes
WO2025133225A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5020040A (en) * 1987-06-24 1991-05-28 Digital Equipment Corporation Overwriting system for magneto-optical recording with self timing track
US4812590A (en) * 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2292902C (en) 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
JP4629671B2 (ja) 2003-07-23 2011-02-09 ピーピージー・インダストリーズ・オハイオ・インコーポレイテッド 複合封止装置および窓組立体
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
CA2567478C (en) 2004-05-24 2014-04-01 Institut De Cardiologie De Montreal Labelled adrenomedullin derivatives and their use for imaging and therapy
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8273325B2 (en) * 2006-12-20 2012-09-25 Ge Healthcare As Contrast agents
DK2155781T3 (da) 2007-05-11 2013-06-17 Inst Cardiologie Montreal Mærkede adrenomedullinderivater og deres anvendelse til visualisering og terapi
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
BR112014010806A2 (pt) * 2011-11-03 2017-05-02 Bayer Ip Gmbh ligadores à base de tirosina para a ligação reversível de peptídeos

Also Published As

Publication number Publication date
SI3075395T1 (en) 2018-03-30
BR112014010708A2 (pt) 2017-04-25
PE20181493A1 (es) 2018-09-18
US9603936B2 (en) 2017-03-28
AR088582A1 (es) 2014-06-18
DK2773376T3 (en) 2016-04-18
UY37922A (es) 2018-11-30
EA201600495A1 (ru) 2016-10-31
SG11201400924TA (en) 2014-09-26
RS56819B1 (sr) 2018-04-30
MY194197A (en) 2022-11-21
US20170204137A1 (en) 2017-07-20
UY34419A (es) 2013-05-31
IL258229A (en) 2018-06-28
KR20150000462A (ko) 2015-01-02
ME02379B (me) 2016-06-20
HK1246147A1 (zh) 2018-09-07
TW201720467A (zh) 2017-06-16
AU2017203423B2 (en) 2019-01-31
ECSP18071104A (es) 2018-10-31
EP3075395A1 (en) 2016-10-05
US10035818B2 (en) 2018-07-31
JP2014532682A (ja) 2014-12-08
AR113830A2 (es) 2020-06-17
TW201332573A (zh) 2013-08-16
KR20180108892A (ko) 2018-10-04
DK3075395T3 (en) 2018-02-19
JP6177975B2 (ja) 2017-08-09
CN107412740B (zh) 2021-02-09
US20160367636A1 (en) 2016-12-22
MX361287B (es) 2018-12-03
TN2014000185A1 (en) 2015-09-30
EA029410B1 (ru) 2018-03-30
NO3075395T3 (enExample) 2018-04-21
EP3075395B1 (en) 2017-11-22
EP2773376B1 (en) 2016-01-13
CY1119897T1 (el) 2018-06-27
CN107412740A (zh) 2017-12-01
JO3385B1 (ar) 2019-03-13
ES2659195T3 (es) 2018-03-14
IN2014CN03290A (enExample) 2015-07-03
BR112014010708B1 (pt) 2021-03-02
IL258229B (en) 2020-02-27
MX350341B (es) 2017-09-04
HUE036535T2 (hu) 2018-07-30
US9649363B2 (en) 2017-05-16
EP2773376A1 (en) 2014-09-10
SG10201607516SA (en) 2016-10-28
MY173372A (en) 2020-01-21
IL232037B (en) 2018-12-31
MX2014004384A (es) 2014-04-30
ZA201600434B (en) 2017-05-31
SI2773376T1 (sl) 2016-05-31
HRP20160285T1 (hr) 2016-04-22
IL252281B (en) 2021-01-31
PL2773376T3 (pl) 2016-07-29
PE20141219A1 (es) 2014-09-13
NZ714621A (en) 2017-10-27
CU20140051A7 (es) 2014-10-02
JP5995984B2 (ja) 2016-09-21
EA025631B1 (ru) 2017-01-30
IL252281A0 (en) 2017-08-31
NZ622997A (en) 2015-12-24
CN103998063A (zh) 2014-08-20
JP2017014264A (ja) 2017-01-19
HRP20180319T1 (hr) 2018-03-23
TWI653051B (zh) 2019-03-11
CY1117354T1 (el) 2017-04-26
DOP2014000078A (es) 2014-07-15
KR101965467B1 (ko) 2019-04-03
CU24184B1 (es) 2016-07-29
EA201400528A1 (ru) 2014-10-30
LT3075395T (lt) 2018-02-26
CA2854134A1 (en) 2013-05-10
IL232037A0 (en) 2014-05-28
TR201802124T4 (tr) 2018-03-21
UA111098C2 (uk) 2016-03-25
AU2012331244B2 (en) 2017-06-15
CN103998063B (zh) 2016-09-21
ECSP14013326A (es) 2014-05-31
MA35618B1 (fr) 2014-11-01
PL3075395T3 (pl) 2018-04-30
RS54623B1 (sr) 2016-08-31
KR102004668B1 (ko) 2019-07-26
CL2014000948A1 (es) 2014-09-05
DOP2018000203A (es) 2018-10-15
HUE027333T2 (en) 2016-09-28
CA2854134C (en) 2020-04-21
US20140287984A1 (en) 2014-09-25
JOP20190001B1 (ar) 2022-03-15
AU2012331244A1 (en) 2014-04-17
GT201400085A (es) 2015-03-05
PH12014500998A1 (en) 2014-06-09
ES2568063T3 (es) 2016-04-27
CR20140184A (es) 2014-05-27
AU2017203423A1 (en) 2017-06-08
WO2013064508A1 (en) 2013-05-10
JOP20190001A1 (ar) 2017-06-16
TWI583396B (zh) 2017-05-21
PT3075395T (pt) 2018-02-13

Similar Documents

Publication Publication Date Title
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
BR112014002118A2 (pt) dispositivo de revestimento retrátil e expansível
IL232247A0 (en) Polypeptide constructs and uses thereof
CO6930362A2 (es) Compuesto heterocíclico y su uso
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
IL230612B (en) Retractable roof
CO6781486A2 (es) Compuestos y su uso
BR112014005406A2 (pt) composição de vacina e respectivo uso
EP2695743A4 (en) MECHANICAL PIN
DE112011103448A5 (de) Faltschachtel
EP2684915A4 (en) STRUCTURE ON POLYETHYLENE BASE
CR20140362A (es) Fenilimidazopirazoles sustituidos y su uso
BRPI1011036A2 (pt) uso
DK2855530T3 (da) Anti-transglutaminase 2-antistoffer
EP2689364A4 (en) Portable truck tester
BR112014014504A2 (pt) uso de partícula
FIU20110075U0 (fi) Pikapeite
BR112014016930A8 (pt) compostos tetrazol-5-il- e triazol-5-il-arila e uso destes como herbicidas
ES2609459T8 (es) Compuestos heterocíclicos condensados y su uso
FR2961761B1 (fr) Accoudoir escamotable
CO6950489A2 (es) Formulación agroquímica y uso de la misma
BR112015008353A2 (pt) uso cosmético e métodos cosméticos
CO6930365A2 (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos
FR2974058B1 (fr) Quille de bateau escamotable
FR2961227B1 (fr) Perfectionnement aux hourdis moules